MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
REGENXBIO Inc. (NASDAQ:RGNX), formerly, ReGenX Biosciences*
Organization & Developments: REGENXBIO
Parents
REGENXBIO Inc. (NASDAQ:RGNX), formerly, ReGenX Biosciences*
Children
*Effort to Translate the Latest Gene Delivery Research into Therapeutic Applications for Diseases
*It's quite promising that over 12 different companies are employing NAV to innovate gene therapies for +20 different indications.
*novel therapeutics and research tools based on rAAV (recombinant adeno-associated ) vectors.
*ReGenX Biosciences
*REGENX’s proprietary technology uses recombinant adeno-associated viral (rAAV) vectors for the delivery of new genetic materials to cells.
*REGENXBIO currently has exclusive rights to more than 100 patents and patent applications worldwide covering its NAV Vectors
*The company focuses on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy.
*The company was formerly known as REGENX Biosciences
*The company's main asset is its NAV Technology Platform.
2017: REGENXBIO: Savvy Acquisition By Management And Plenty Of Irons In The Fire - REGENXBIO (NASDAQ:RGNX)
2018: Regenxbio Part I: A Novel Gene Therapy Innovator With Substantial Unlocked Value - REGENXBIO (NASDAQ:RGNX)
2018: REGENXBIO: An Underappreciated Leader In Gene Editing_seekingalpha.com
2019: Big Pharma Has Mad Love For These 2 Biotechs_Regenxbio, Denali
2019: IBI Research On Regenxbio: Temporary Difficulty Leads To Opportunity_seekingalpha.com
2019: Regenxbio And RGX-501 In Homozygous Familial Hypercholesterolemia_seekingalpha.com
2019: RegenxBio runs into partial hold for anti-VEGF gene therapy as FDA investigates delivery device – Endpoints News
2019: Regenxbio: More To Come After Zolgensma Approval_seekingalpha.com
2019: Regenxbio's Wet AMD Data Is Encouraging, With Majority Of Patients Free Of Rescue Injections_seekingalpha.com
2020: Regenxbio: Championing Gene Therapy
2020: Regenxbio: More Robust Data For Wet AMD
2021: Regenxbio: An Overlooked Gene Therapy Innovator
2022: Regenxbio: A Transformative Year_seekingalpha.com
2022: Regenxbio: Great R&D, Lack Of Near-Term Catalysts_seekingalpha.com
2022: Regenxbio: Suprachoroidal Data Is Still The Key_seekingalpha.com
2023: REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results
2023: Regenxbio: Buy, High-Potential Stock Stagnant Due To No Near-Term Catalysts_ seekingalpha.com
2023: Regenxbio: Promising Yet Risky Therapeutic Horizon (NASDAQ:RGNX)
2023: Restructuring plan, including a 15% reduction in workforce, expected to result in total savings of at least $100 million
2024: FDA endorses speedy approval path for Regenxbio Duchenne gene therapy
2024: RegenxBio touts positive data for rare disease drug RGX-121
2024: Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform
2024: Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder_seekingalpha
2024: Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips_ seekingalpha.com
2024: REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track_ seekingalpha.com
2024: Ruling in REGENXBIO-Sarepta Patent Case Threatens Gene Therapy Market
2025: Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again
2025: Regenxbio Secures A Partnership With Nippon Shinyaku For RGX-111 & 121
2025: Regenxbio: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026
2025: Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrom
Jumps
*Key People: REGENXBIO
Finance & Acquisitions: REGENXBIO